期刊文献+

人IL-21cDNA的克隆及重组腺病毒表达载体的构建 被引量:4

CLONING OF IL-21 GENE AND CONSTRUCTION OF RECOMBINANT IL-21 GENE ADENOVINES EXPRESSION VECTOR
下载PDF
导出
摘要 目的:构建含人IL-21基因的重组腺病毒表达载体,为IL-21基因治疗肿瘤研究奠定基础。方法:从人外周血淋巴细胞提取总RNA,经RT-PCR扩增IL-21基因片段,将其连接到进入载体pENTR1A,然后经LR重组转入到腺病毒表达载体pAd/CMV/V5-DEST中,构建含IL-21基因的腺病毒载体(Ad-IL-21),并进行测序鉴定和PCR鉴定。结果:Ad-IL-21表达载体测序结果与GenBank中IL-21基因序列一致,Ad-IL-21经PCR扩增出IL-21基因片段。结论:成功构建携带人IL-21基因的重组腺病毒表达载体。 Objective.To be as the foundation of the tumor therapy with targeting IL-21 gene by constructing of recombinant interleukin 21 gene adenovirus expression vector. Methods. Total RNA was extracted from human peripheral blood lymphocyte. IL-21 gene was amplified by RT-PCR and linked with pENTR1A vector. The constructed vector pENTRIA- IL-21 and adenovirus vector pAd/CMV/VS-DEST were recombined by LR recombinant technique to construct the recombined IL-21 gene adenovirus expression vector(Ad-IL- 21). Ad-IL-21 was identified by DNA sequencing and PCR method. Result.DNA sequence of IL-21 gene of Ad- IL-21 adenovirus vector was in accordance with that of IL-21 gene in GenBank database. IL-21 gene fragment of Ad- IL-21 vector was amplified by PCR. Conclusion.The recombinant Ad-IL-21 expression vector could express IL-21 gene and was constructed successfully.
出处 《广西医科大学学报》 CAS 2009年第4期516-518,共3页 Journal of Guangxi Medical University
基金 天津市自然科学基金资助项目(No.09JCYBJC09300) 中国医学科学院放射医学研究所基金资助项目(No.ST0721)
关键词 IL-21基因 基因克隆 腺病毒表达载体 LR重组反应 IL-21 gene gene clone adenovirus expression vector LR recombination reaction
  • 相关文献

参考文献9

  • 1Parrish-Novak J,Dillon SR,Nelson A,et al.Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function[J].Nature,2000,408(6808):57-63.
  • 2De Groot-Kruseman HA,Klepper M,Mol WM,et al.Intragraft mRNA expression of the novel cytokine IL-21 during acute rejection after clinical heart transplantation[J].J Heart Lung Transplant,2003,21(2):165.
  • 3Vollmer TL,Liu R,Price M,et al.Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen[J].J Immunol,2005,174(5):2 696-2 701.
  • 4Ma HL,Whitters MJ,Konz RF.IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma[J].J Immunol,2003,171(2):608-615.
  • 5Asao R,Kudo T,Makabe K,et al.Antitumor activity of interleukin 21 prepared by novel refolding procedure from inclusion bodies expressed in Escherichia coli[J].FEBS Lett,2002,528(1-3):70-76.
  • 6范凌云,谢庆军.腺病毒载体的研究进展[J].中国生物制品学杂志,2008,21(2):153-157. 被引量:21
  • 7彭朝晖,张晓志.国外重组腺病毒-p53制品对肿瘤基因治疗临床研究的概况[J].中华医学杂志,2003,83(23):2098-2100. 被引量:37
  • 8Li JH,Chia M,Shi W,et al.Tumor-targeted gene therapy for nasopharyngeal carcinoma[J].Cancer Res,2002,62(1):171-178.
  • 9Sasaki Y,Sone T,Yoshida S,et al.Evidence for high specificity and efficiency of multiple recombination signals in mixed DNA cloning by the Multisite Gateway system[J].J Biotechnol,2004,107(3):233-243.

二级参考文献58

  • 1夏忠军,常建华,张力,姜文奇,管忠震,刘基巍,张阳,胡晓桦,吴国华,王华庆,陈正常,陈建超,周清华,陆建伟,樊青霞,黄建瑾,郑晓.基因工程腺病毒(H101)瘤内注射联合化疗治疗头颈部及食管鳞癌的Ⅲ期临床研究[J].癌症,2004,23(12):1666-1670. 被引量:50
  • 2叶迅,陆琴,赵毅,任臻,孟夏,葛盛芳,邱祺宏,童涌,LIEBER ANDRE,梁旻,胡放,陈红专.嵌合型E1B55-kDa蛋白缺陷型腺病毒载体治疗肿瘤的评价(英文)[J].生物化学与生物物理进展,2005,32(12):1156-1164. 被引量:5
  • 3Clayman GL, el-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol, 1998, 16:2221-2232.
  • 4Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst, 1999, 91:763-771.
  • 5Chada S, Mhashilkar A, Roth JA, et al. Development of vaccines against self-antigens: the p53 paradigm. Curr Opin Drug Discov Devel, 2003, 6:169-173.
  • 6Martin B, Bradly GW. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res,1999, 59: 1391-1399.
  • 7Martin LS, Young RS. p53 regulation of DNA excision repair pathways. Mutagenesis, 2002, 17: 149-156.
  • 8Introgen′s Intrabronchial Advexin therapy demonstrates safety and clinical activity in bronchoalveolar lung cancer. Introgen Therapeutics, Inc. News Release, 2003-06-02.
  • 9Phase 2 breast cancer study shows clinical responses in 90 percent of patients treated with Introgen′s Advexin therapy. Introgen Therapeutics, Inc. News Release, 2003-06-02.
  • 10Buller RE, Runnebaum IB, Karlan BY, et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 2002,9:553-566.

共引文献56

同被引文献24

  • 1JunDou,GuobinChen,JingWangt,FengshuZhao,JunsongChen,XuesongFang,QuanTang,LiliChu.Preliminary Study on Mouse Interleukin-21 Application in Tumor Gene Therapy[J].Cellular & Molecular Immunology,2004,1(6):461-466. 被引量:14
  • 2苗莉,缪竞诚.细胞因子在急性辐射损伤治疗中的作用[J].国际放射医学核医学杂志,2006,30(3):173-176. 被引量:7
  • 3Vollmer TL , Liu R , Price M , et al. Differential effects of IL -21 during initiation and progression of autoimmunity against neuroantigen [ J ]. J Immunol , 2005 , 174 (5) : 2 696 - 2 701.
  • 4Asao R , Kudo T , Makabe K, et al. Antitumor activity of interleukin 21 prepared by novel refolding procedure from inclusion bodies expressed in Escherichia coli [ J ] . FEBS Lett , 2002 , 528 (1 -3) :70-76.
  • 5Keall PJ, Lammering G, Lin PS, et al. Tumor control proba- bility Prediction for genetic radiotherapy[ J]. Int J Radiat Oncol Biol Phys ,2003,57 ( 1 ) :255 - 263.
  • 6Sondergaard H , Frederiksen KS, Thygesen P, et al. Interleu- kin 21 therapy increases the density of tumor infiltrating CD^8 + T cells and inhibits the growth of syngeneic tumors[ J]. Cancer Immunol Immunother, 2007 , 56(9) :1 417 -1 428.
  • 7Sondergaard H, Skak K. IL- 21: roles in immunopathology and cancer therapy [ J ] . Tissue Antigens,2009,74 (6) :467 - 479.
  • 8Zotos D, Conquet JM, Zhang Yet al. IL-21 regulates germinal center B cell differentiation and proliferation through a B cellintrinsic mechanism[J]. J Exp Med,2010,207(2) :365 -378.
  • 9Parrish - Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are invovled in NK cell expansion and regulation of lymphocyte function [ J ]. Nature, 2000,408 (8) :57 - 63.
  • 10Ugai S, Shimozato O, Yu L, et al. Transduction of the IL -21 and IL- 23 genes in human pancreatic carcinoma cells produces natural killer cell - dependent and independent antitumor effects [J]. Cancer Gene Ther, 2003, 10(10) :771 -778.

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部